Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of oral rilzabrutinib in adults and adolescents with persistent or chronic immune thrombocytopenia
CTR20220447Phase 3Completed
- Sponsor
- Principia Biopharma
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rilzabrutinib in immune thrombocytopenia (ITP), sponsored by Principia Biopharma. Started Oct 2022; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20220447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220447.